Loading stock data…
$28.09
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Cogent Biosciences, Inc. in the Healthcare sector is trading at $28.09 with a market capitalization of $4.9B. Wall Street consensus targets $55.82 (11 analysts), implying a +98.7% move over the next 12 months. The stock is currently 36% below its 52-week high of $43.73, remaining 22.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$102.64M↑ | -$103.61M↓ | -$99.49M↓ | -$83.36M↓ | -$75.58M |
| Net Income | -$96.41M↑ | -$97.35M↑ | -$102.49M↓ | -$80.93M↓ | -$73.53M |
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase ...